Video

Dr. Abou-Alfa on the FDA Approval of Cabozantinib in HCC

Author(s):

Ghassan K. Abou-Alfa, MD

In Partnership With:

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the FDA approval of cabozantinib (Cabometyx) is likely to shake up the landscape and impact sequencing for patients with hepatocellular carcinoma (HCC).

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the FDA approval of cabozantinib (Cabometyx) is likely to shake up the landscape and impact sequencing for patients with hepatocellular carcinoma (HCC).

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Erminia Massarelli, MD, PhD, MS
Karen L. Reckamp, MD, MS
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Lori Wirth, MD
Tanios Bekaii-Saab, MD, FACP
Moritz Fürstenau, MD
Jun Gong, MD
Thierry Facon, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Related Content
Moitreyee Chatterjee-Kishore, PhD, MBA, of Astellas
July 26th 2024

Zolbetuximab Plus Chemo Approaches EU Approval for Advanced Gastric/GEJ Cancer

Nam Bui, MD, sarcoma specialist, clinical assistant professor, medicine, Stanford Cancer Institute; Ciara Kelly, MBBCh, BAO, interim clinical director, Sarcoma Oncology Service, Memorial Sloan Kettering Cancer Center
July 18th 2024

Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa

Hansoo Park, MD, PhD, MS, of Gwangju Institute of Science and Technology
July 25th 2024

Fecal Microbiota Transplants May Enhance Immunotherapy Efficacy in GI Cancers

Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
June 6th 2024

Paik Provides Insights Into Tepotinib Treatment in NSCLC Harboring MET Exon 14 Skipping Alterations

Tanios S. Bekaii-Saab, MD, FACP, of the Mayo Clinic
July 19th 2024

Complexity in GI Cancer: Questions Are Answered in Gastroesophageal Cancer, Remain in HCC

RMC-6236 in Previously Treated PDAC
July 16th 2024

RMC-6236 Shows Activity With Favorable Toxicity Profile in Previously Treated PDAC